,olaparib,trastuzumab deruxtecan
merck,astrazeneca,daiichi sankyo
['tnbc', 'olaparib', 'bcsm', 'enhertu', 'daiichisankyous', 'astrazenecaus', 'astrazeneca']
 enhertu was granted breakthrough designation by fda for her2 low in april so will be quick. i am hopeful insurances will approve. we saw something similar when data presented last year for olaparib for early stage tnbc and insurance covered without fda approval. #asco22 #bcsm
Breast & gyn med onc @valleyhospital in NJ. Focus on survivorship and ?????? onc. All opinions my own. Retweets not endorsements. Host of INTERLUDE podcast ??